我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

厄贝沙坦治疗慢性心力衰竭的疗效观察

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2009年第2期
页码:
264
栏目:
临床研究
出版日期:
2009-03-30

文章信息/Info

Title:
Observations on efficacy of irbesartan in treatment of chronic heart failure
作者:
郭宪清1; 张丽香2; 房立丽3
大庆市人民医院：1.用药指导办公室，2.药剂科，3.心内科，黑龙江 大庆 163316
Author(s):
GUO Xian-qing1;  ZHANG Li-xiang2;  FANG Li-li3
1.Drug Administration Office, 2.Department of Pharmacy, 3.Department of Cardiology, Daqing People’s Hospital, Daqing 163316, Heilongjiang, China
关键词:
厄贝沙坦; 治疗; 心力衰竭
Keywords:
irbesartan;  treatment;  heart failure
分类号:
R541.61
DOI:
-
文献标识码:
A
摘要:
目的 观察常规治疗的基础上加用厄贝沙坦治疗慢性心力衰竭(CHF)患者的临床疗效。方法 78例CHF患者随机分为两组。对照组给予强心、利尿等治疗，试药组在此基础上加用厄贝沙坦。治疗90 d后观察临床疗效、血压(BP)、心率(HR)、心胸比率变化及超声心动图参数变化。结果 试药组总有效率88%，明显高于对照组(P＜0.05)。试药组心功能的改善明显优于对照组(P＜0.05)，副作用比较轻微。结论 厄贝沙坦治疗CHF安全有效。可作为治疗CHF的一线药物。
Abstract:
AIM To observe the clinical efficacy of conventional treatment plus irbesartan in the treatment of patients with chronic heart failure（CHF）. METHODS A total of 78 CHF patients were randomly divided into two groups. The control group was given conventional treatment and the irbesartan group was given conventional treatment plus irbesartan. After 90 days’ treatment, the clinical efficacy, blood pressure (BP), heart rate (HR), cardio-thoracic ratio and echocardiography parameters were observed and compared between the 2 groups. RESULTS The efficiency of the irbesartan group was 88 percent, significantly higher than that of the control group (P<0.05). The heart function of the irbesartan group was significantly better improved than that of the control group(P<0.05) and fewer side effects were found in the irbesartan group. CONCLUSION Irbesartan is safe and effective in the treatment of CHF and can be used as first-line treatment for CHF.

参考文献/References

[1］ Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group［J］. Lancet, 2000, 355(9215):1575-1581.

［2］ 戴闺柱. 慢性收缩性心力衰竭治疗建议［J］． 中华心血管病杂志， 2002， 30(1)：7-23．

［3］ Burlew BS,Weber KT.Cardiac fibrosis and diastolic dysfunction［J］. Herz, 2002, 27(2):92-98.

［4］ Weber MA. The 24-hour blood pressure pattem: does it have implications for morbidity and mortality?［J］. Am J Cardiology, 2002, 89(2A):27A-33A.

［5］ 范珂,王浩,张莉霞. 替米沙坦的降压作用及对左心室肥厚的影响［J］. 临床荟萃, 2005, 20(7):385-386.

备注/Memo

备注/Memo:
收稿日期：2008-6-30.作者简介：郭宪清，副主任药师，硕士 Email:guoxianqing990@163.com
更新日期/Last Update: 2009-04-16